We no longer support this browser. Using a supported browser will provide a better experience.

Please update your browser.

Close browser message

Treasury and Payments

Improve your working capital, reduce fraud and minimize the impact of unexpected disruptions with our treasury solutions—from digital portals to integrated payables and receivables—all designed to make your operations smoother and more efficient.

Learn more about our treasury solutions:

Credit and Financing

Prepare for future growth with customized loan services, succession planning and capital for business equipment or technology.

Learn more about our credit and financing solutions:

Commercial Real Estate

Get the strategic support to be successful throughout market and real estate cycles with insights, hands-on service, comprehensive financial solutions and unrivaled certainty of execution.

Learn more about our commercial real estate solutions:

International Banking

Global opportunities mean global challenges. But real success means understanding the local markets you serve—which is why we bring the business solutions, insights and market perspective you need. 

Learn more about our international banking solutions:

Startups

Biopharma and medtech deal activity continued to slow in Q3

Our biopharma and medtech reports offer overviews of upfront cash, IPOs, potential acquisitions and other trends we may see throughout the remainder of 2022.


Biopharma R&D partnerships, medtech and overall dealmaking continued to decline across the subsectors in the third quarter of 2022. 

J.P. Morgan's biopharma therapeutics and medtech licensing reports examine activity in each sector to provide insights on industry trends. The reports, powered by DealForma, highlight:

  • Deal values in biopharma licensing partnerships
  • Trends in deal values for medical devices, diagnostics, digital health therapies and research tools
  • Venture investment amounts in therapeutic and platform companies
  • The advanced therapies that are seeing healthy investment and dealmaking
  • IPO and M&A activity in each sector

Download the full reports to understand these life sciences dealmaking trends and see what they may mean for the months ahead.

Technology and Disruptive Commerce Healthcare IPO Markets and Economy Life Sciences Startups Credit and Financing

Get in Touch and Stay Informed

icon
Loading...